Sporos BioDiscovery to Present at the Oppenheimer 33rd Annual Healthcare Conference
09 Mar 2023
HOUSTON--(BUSINESS WIRE)-- Sporos BioDiscovery, Inc. (a wholly owned affiliate of Sporos Bioventures, “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic programs targeting cancer vulnerabilities in the tumor and tumor microenvironment, today announced the company’s Executive in Residence, Stephen Rubino, Ph.D., will present a company overview on Wednesday, March 15, 2023, at 12:40 p.m. ET at the Oppenheimer 33rd Annual Healthcare Conference, which will take place virtually.
To access the live webcast of this presentation, please select this link, or visit the News & Events page of Sporos Bioventures website . A replay of the webcast will be available on the website for 90 days following the event.
About Sporos BioDiscovery
Sporos BioDiscovery, Inc. is a biotechnology research & development company with a diversified pipeline of several small molecule precision oncology therapeutic programs in development, including its lead candidate SPR1, a novel TEAD inhibitor program. Sporos BioDiscovery is a wholly-owned affiliate company of Sporos Bioventures, LLC, a private biotechnology company focused on transforming the drug development process across oncology.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.